Previous Close | 1.1800 |
Open | 1.1600 |
Bid | 1.2000 x 3000 |
Ask | 1.3000 x 1000 |
Day's Range | 1.1600 - 1.3000 |
52 Week Range | 1.0600 - 16.8300 |
Volume | |
Avg. Volume | 857,968 |
Market Cap | 5.002M |
Beta (5Y Monthly) | 0.86 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
-- Study finds significant improvement in gait deficit in multiple sclerosis patients using translingual neurostimulation (“PoNS Therapy®”) combined with a therapeutic exercise program -- -- Poster was one of ten rehabilitation research presentations nominated for the Labe C. Scheinberg Award recognizing the platform or poster, in each therapeutic category, that has the greatest impact in advancing the care of people with MS -- NEWTOWN, Pa., June 06, 2022 (GLOBE NEWSWIRE) -- Helius Medical Techn
New program seeks to expand access to patients suffering from multiple sclerosis (MS)NEWTOWN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its Patient Therapy Access Program (“PTAP”), which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (“PoNS”) Therapy at a significantly reduced price. PoNS is indicate
NEWTOWN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been selected for a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting tak